Target Name: MCIDAS
NCBI ID: G345643
Review Report on MCIDAS Target / Biomarker Content of Review Report on MCIDAS Target / Biomarker
MCIDAS
Other Name(s): multiciliate differentiation and DNA synthesis associated cell cycle protein | Protein Idas | MCIN_HUMAN | multiciliate cell differentiation 1 | MCI | MCIN | protein Idas | Multiciliate differentiation and DNA synthesis-associated cell cycle protein | McIdas protein | CILD42 | IDAS | Multicilin | Multiciliate differentiation and DNA synthesis associated cell cycle protein

MCIDAS: Multi-Cancerous Differentiation and DNA Synthesis Induced Cell Cycle Protein

MCIDAS: A Potential Drug Target and Biomarker for Multi-Cancerous Differentiation and DNA Synthesis Induced Cell Cycle Protein

Abstract:

Multi-cancerous differentiation (MCD) is a critical process in cancer progression, where cancer cells are able to continuously evade the host immune system and continue to promote their growth and proliferation. The regulation of cell cycle proteins is crucial for the maintenance of a balance between cell growth and division, and the deregulation of cell cycle proteins has been implicated in the development and progression of many types of cancer. One of the key proteins involved in cell cycle regulation is the multiciliate differentiation and DNA synthesis associated cell cycle protein (MCIDAS), which has been identified as a potential drug target and biomarker for multi-cancerous differentiation and DNA synthesis. In this article, we will review the functions of MCIDAS, its role in cancer progression, and its potential as a drug target and biomarker.

Introduction:

Multi-cancerous differentiation (MCD) is a critical process in cancer progression, where cancer cells are able to continuously evade the host immune system and continue to promote their growth and proliferation. This process allows cancer cells to develop the ability to reorganize themselves into new and dangerous forms, making them difficult to treat. The regulation of cell cycle proteins is crucial for the maintenance of a balance between cell growth and division, and the deregulation of cell cycle proteins has been implicated in the development and progression of many types of cancer.

One of the key proteins involved in cell cycle regulation is the multiciliate differentiation and DNA synthesis associated cell cycle protein (MCIDAS). MCIDAS is a protein that is expressed in a variety of tissues and is involved in the regulation of cell cycle progression, as well as the control of DNA replication and gene expression.

Functional Characterization of MCIDAS:

MCIDAS is a 21-kDa protein that is expressed in a variety of tissues, including lung, breast, colon, and pancreatic cancer. It is highly conserved across different species, with a calculated pI of 12.9 and a predicted localization in the cytoplasm. MCIDAS is involved in the regulation of cell cycle progression, as well as the control of DNA replication and gene expression.

MCIDAS plays a key role in the regulation of G1 phase, which is a critical stage of cell cycle where the cell prepares for cell division. During G1, MCIDAS helps to regulate the assembly and disassembly of the nuclear envelope, which is necessary for the exchange of genetic and regulatory information between the cytoplasm and the nucleus. Additionally, MCIDAS is involved in the regulation of the G2 phase, which is a critical stage of cell cycle where the cell prepares for cell division by producing mitotic spores.

MCIDAS is also involved in the regulation of DNA replication, as well as gene expression. It has been shown that MCIDAS plays a key role in the regulation of DNA replication, as it is able to interact with the DNA replication complex and prevent its progression through the cycle. Additionally, MCIDAS has been shown to play a role in the regulation of gene expression, as it is able to interact with transcription factors and prevent their from activating target genes.

Drug Targeting and Biomarker Potential:

MCIDAS has been identified as a potential drug target for the treatment of multi-cancerous differentiation and DNA synthesis-induced cell cycle proteins. The deregulation of cell cycle proteins has been implicated in the development and progression of many types of cancer, including multi-cancerous differentiation, and drug targeting MCIDAS may be able to treat these conditions.

MCIDAS has also been identified as a potential biomarker for the diagnosis and prognosis of multi-cancerous differentiation. The levels of MCIDAS have been shown to be elevated in the blood and other tissues of individuals with multi

Protein Name: Multiciliate Differentiation And DNA Synthesis Associated Cell Cycle Protein

Functions: Transcription regulator specifically required for multiciliate cell differentiation (PubMed:25048963). Acts in a multiprotein complex containing E2F4 and E2F5 that binds and activates genes required for centriole biogenesis. Required for the deuterosome-mediated acentriolar pathway (PubMed:25048963). Plays a role in mitotic cell cycle progression by promoting cell cycle exit. Modulates GMNN activity by reducing its affinity for CDT1 (PubMed:21543332, PubMed:24064211)

The "MCIDAS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCIDAS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2